| abstract |
Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-ΤGFβ and/or LΤΒΡ3-ΤGFβ. The application also provides methods of use of these inhibitors for, for example, inhibiting ΤGFβ activation, and treating subjects suffering from ΤGFβ-related disorders, such as fibrotic conditions. Methods of selecting a context- dependent or context-independent isoform-specific ΤGFβ inhibitor for a subject in need thereof are also provided. |